PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: Genentech, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection - Genentech announced that the SUMMACTA study met its primary endpoint
Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection

 

NewswireToday - /newswire/ - South San Francisco, CA, United States, 2012/05/02 - Genentech announced that the SUMMACTA study met its primary endpoint. SIX: RO, ROG; OTCQX: RHHB

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks. A similar proportion of rheumatoid arthritis (RA) patients in each group achieved an ACR20 response at Week 24, a measure indicating improvement in the number of tender and swollen joints, pain scale, patients¿ and physicians¿ assessment of improvement and certain laboratory markers.

"We are very pleased with these data showing that subcutaneous administration of ACTEMRA provides clinically meaningful and comparable results to the IV infusion," said Hal Barron, M.D., chief medical officer and head, Global Product Development. "This may provide patients and their doctors with an important additional treatment option."

Preliminary safety analysis showed that the adverse event profiles of the SC and IV groups were comparable with no new clinically meaningful safety signals identified. Data from SUMMACTA will be submitted for presentation at an upcoming medical meeting. The results of BREVACTA, a second study assessing ACTEMRA SC formulation administered every two weeks versus placebo SC, are anticipated later in 2012. Following completion of the two studies Genentech will evaluate plans to submit SUMMACTA and BREVACTA data to health authorities in the U.S.

About SUMMACTA
SUMMACTA is a randomized, double-blind, active controlled, parallel group, multicenter, two-year study with a double-blind period of 24 weeks with two treatment arms, followed by an open-label period of 72 weeks with some SC and IV switching. The trial is a non-inferiority design and randomized 1,262 patients with moderately to severely active RA who have had an inadequate response to disease-modifying antirheumatic drug (DMARD) therapy that may have included (in up to 20 percent of patients) one or more tumor necrosis factor (TNF) antagonist therapies into two treatment arms. Patients in group A received ACTEMRA 162 mg SC weekly and those in group B received ACTEMRA 8 mg/kg IV every four weeks.

Secondary endpoints include assessments at Week 24 of the proportion of patients in each group with an ACR50 response; an ACR70 response; DAS 28 low disease activity; decrease of ≥ 0.3 in the Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline to Week 24 and the proportion of patients who withdrew due to lack of therapeutic response. Further analysis will assess long-term safety profile and efficacy; pharmacokinetics (PK) and pharmacodynamics (PD) of ACTEMRA SC; immunogenicity of ACTEMRA SC; and the effect of switching from one formulation to another on the safety, efficacy, PK and PD of ACTEMRA.

About ACTEMRA® (tocilizumab)
ACTEMRA is the first humanized IL-6 receptor-inhibiting monoclonal antibody approved for the treatment of adult patients with moderately to severely active RA who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. The extensive ACTEMRA clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries, including the United States. In addition, ACTEMRA is also approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients two years of age and older.

Important Safety Information
Some people have serious infections while taking ACTEMRA, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.

Other serious side effects of ACTEMRA include tears (perforation) of the stomach and intestines, changes in blood test results, hepatitis B infection becoming an active infection again, and nervous system problems.

Serious allergic reactions, including death, can happen with ACTEMRA. These reactions may happen with any infusion of ACTEMRA even if they did not occur with an earlier infusion. Patients must tell their doctor if they have had a previous reaction to ACTEMRA. Patients should not take ACTEMRA if they are allergic to it or any of its ingredients. Common side effects with ACTEMRA in rheumatoid arthritis include upper respiratory tract infections (common cold, sinus infections), headache, and increased blood pressure (hypertension).

Common side effects with ACTEMRA in SJIA include upper respiratory tract infections (common cold, sinus infections), headache, and diarrhea.

Patients must tell their healthcare providers if they plan to become pregnant or are pregnant. It is not known if ACTEMRA will harm an unborn baby. Genentech has a registry for pregnant women who take ACTEMRA. Patients who are pregnant or become pregnant while taking ACTEMRA must contact the registry at 1-877-311-8972 and talk to their healthcare provider.

Patients must call their healthcare provider for medical advice about any side effects. Patients or caregivers may report side effects to the FDA at 1-800-FDA-1088. Patients or caregivers may also report side effects to Genentech at 1-888-835-2555.

For additional important safety information, including Boxed WARNINGS and Medication Guide, please call 1-800-ACTEMRA (228-3672).

ACTEMRA (actemra.com) is part of a co-development agreement with Chugai Pharmaceutical Co. and has been approved in Japan since June 2005. ACTEMRA is approved in the European Union, where it is known as RoACTEMRA, and several other countries, including India, Brazil, Switzerland and Australia.

About Genentech
Founded more than 30 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Genentech, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Genentech | ACTEMRA
Publisher Contact: Press Office - Gene.com 
650-225-1000 press[.]gene.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Genentech, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Genentech, Inc. / Company Profile


Read Research Most Recent Related Newswires:

DSM-Niaga Ready for Commercial Scale Production of 100%-recyclable Carpets
DSM Dyneema Introduces Whole New Level of Cut Protection with Black Dyneema® Diamond Technology
DSM Presents Sustainable and Healthy Dairy Solutions At FoodTech 2016
Frost & Sullivan Highlights GENEWIZ's Commitment to Providing Cutting-edge Services in the Life Science Research Services Market
DSM to Present its Latest Advances in Skin Biochemistry At IFSCC Conference
DSM Launches ForTii® Ace Next Generation High Performance Polyamides
DSM Launches New Cultures to Reduce Cheese Ripening Time
DSM Launches New 3C Technology to Reinvigorate Omega-3 Supplements Category
DSM to Highlight its Health and Indulgence Solutions for Baked Goods At IBIE
DSM Welcomes EU Novel Foods Approval for Heart Health Antioxidant
DSM Dyneema Successfully Defends Key Patent Against Competitor Challenge
DSM Expands its Automotive Electronics Portfolio with High-flow Akulon PA66
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions
BD Announces New Software Release for Pyxis Enterprise Solution
DSM Opens its Asia Pacific Personal Care Technical & Application Center in Shanghai

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)